5th Antiviral Drug Discovery and Development Summit.
The 5th Antiviral Drug Discovery and Development Summit provided an up-to-date snapshot of the ongoing developments in the area. The topics covered ranged from updates on recently launched drugs (Kaletra), Fuzeon) and new investigational inhibitors (T-1249, Reverset, UK-427857, L-870810, PA-457, remofovir, VX-950), to the discovery of new antiviral targets and advances in technologies that may provide the substrate for the next generation of therapeutics. It is apparent from the range of presentations that much of today's efforts are focused on developing new classes of HIV inhibitors (gp41, integrase), while there is also considerable progress in hepatitis C, where a number of inhibitors have or should reach proof-of-concept studies in the coming months. Here we provide the highlights of this meeting, with particular emphasis on the new developments in HIV and hepatitis C virus.
Blair
Wade
W
Anti-infectives Biology, Sandwich Laboratories, Pfizer Global R&D, Ramsgate Road, Sandwich, Kent, CT13 9PH, UK.
Perros
Manos
M
D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D051381:Rats
D000998:Antiviral Agents; D015507:Drugs, Investigational